Heat Biologics Announces Addition of Former US Senator Mark Pryor to Biothreat Advisory Board

DURHAM, N.C., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, announces the addition of Mark Pryor, former US Senator from the State of Arkansas, to the Company’s Biothreat Advisory Board.

Former US Senator Mark Pryor currently serves with the premier law firm, Brownstein Hyatt Farber Schreck. He is a former two-term U.S. senator and Arkansas attorney general. During his 12 years representing Arkansas in the Senate, he worked across the aisle to pass more than 70 pieces of legislation on a range of critical issues, including homeland security and defense. Sen. Pryor served on several high-profile committees during his tenure, including Appropriations; Armed Services; Commerce, Science and Transportation; Homeland Security and Governmental Affairs.

Jeff Wolf, Chief Executive Officer of Heat, commented, “As a leader on the Armed Services as well as the Homeland Security and Governmental Affairs committees, Senator Pryor brings unique expertise in policy and government affairs to our biothreat efforts. We look forward to leveraging Senator Pryor’s knowledge as we advance our new biothreat initiatives.”

Senator Pryor joins David Lasseter, Former Deputy Assistant Secretary of Defense for Countering Weapons of Mass Destruction; Former US Representative Jack Kingston, who also serves as the Secretariat of the Alliance for Biosecurity; Andrew C. Weber, Former Assistant Secretary of Defense for Nuclear, Chemical & Biological Defense Programs; and Dr. Gregory Koblentz, Associate Professor at George Mason University and leading expert on chemical and biological weapons. 

About Heat Biologics, Inc.
Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. Heat’s gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in a Phase 2 trial, various infectious disease/biological threat programs in preclinical development and a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.

For more information, please visit: www.heatbio.com, and also follow us on Twitter.

Forward Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectation, and assumptions and include statements regarding the contributions to be made by Mark Pryor the advisory board and leveraging Senator Pryor’s knowledge as Heat advances its new biothreat initiatives. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability of Heat to successfully develop a new biosecurity/biodefense initiative and benefit from the contributions of the advisory board, the ability of Heat's therapies to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, especially in light of COVID-19, Heat's ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to Heat's ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, Heat's ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities and its cash and short-term investments providing significant runway to fund Heat’s current clinical programs and further expand Heat’s therapeutic portfolio , its ability to continue to maintain its listing on the Nasdaq Capital Market and its ability to retain its key scientists or management personnel, and the other factors described in Heat's annual report on Form 10-K for the year ended December 31, 2020 filed with the SEC, and other subsequent filings with the SEC. The information in this release is provided only as of the date of this release, and Heat undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

Media and Investor Relations Contact
David Waldman
+1 919 289 4017
investorrelations@heatbio.com

Released August 23, 2021